Raloxifene for Gyno: Interesting read--->

wayner

Convo Lounge Moderator
http://www.pslgroup.com/dg/200B2E.htm


"In the study, 14 subjects received tamoxifen 10-20 mg/day for three to six months, while nine subjects received 60 mg/day of raloxifene for three to six months. A group of 13 received no medications and were used as a control group.

The mean age of these boys was 14 years, and all were of normal body mass index. Those who received tamoxifen had had the condition for a mean period of 18.9 months, while those randomized to raloxifene had the condition for an average of 37.2 months.

Both of these estrogen receptor blockers were effective in treating gynecomastia, although the response was greater for raloxifene. In the tamoxifen group, the mean nodule size was 4.6 cm before treatment and 2.1 cm post-treatment, for a reduction in size of 56 percent.

In the raloxifene group, pre-treatment nodule size was 4.9 cm and post-treatment size was 1.6 cm -- a reduction in size of 73 percent. It was not stated over what period of time these changes occurred. "


Anybody use this?

Is this the chemical name for something already available?
 
Interesting. It looks like raloxifene hydrochloride is used primarily in the treatment of Osteoporosis.
Here is some information I have found.

EVISTA® (raloxifene HCl) Prevents and Treats Osteoporosis in Women Past Menopause

EVISTA is neither an estrogen nor a hormone. EVISTA is a Selective Estrogen Receptor Modulator, or SERM. It helps build bone without negatively affecting the breast or uterus.

EVISTA actually stops the thinning of bone and builds it, making your bones stronger and less likely to break.

Millions of prescriptions for EVISTA have been filled since the FDA approved it in 1997.

EVISTA has been shown to decrease the risk of fracture, and while preventing and treating osteoporosis in women who are past menopause, EVISTA also...

Lowers cholesterol

EVISTA lowers total cholesterol by about 7% and LDL (bad) cholesterol by about 11%. It does not change HDL (good) cholesterol. (The effect of EVISTA on risk for cardiovascular disease is currently under study.)

Does not increase the risk of breast or uterine cancer

Women taking EVISTA had no increased risk of breast or uterine cancer in clinical studies

Does not cause breast tenderness or vaginal bleeding

Women taking EVISTA and women taking placebo (sugar pill) experienced no difference in breast tenderness or vaginal bleeding in clinical studies


EVISTA® (raloxifene hydrochloride) is a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds.

The chemical designation is methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzothien-3-yl]-[ 4-[ 2-( 1-piperidinyl) ethoxy] phenyl]-, hydrochloride. Raloxifene hydrochloride (HCl) has the empirical formula C28H27NO4S • HCl, which corresponds to a molecular weight of 510.05. Raloxifene HCl is an off-white to pale-yellow solid that is very slightly soluble in water.

EVISTA is supplied in a tablet dosage form for oral administration. Each EVISTA tablet contains 60 mg of raloxifene HCl, which is the molar equivalent of 55.71 mg of free base. Inactive ingredients include anhydrous lactose, carnauba wax, crospovidone, FD& C Blue No. 2 aluminum lake, hydroxypropyl methylcellulose, lactose monohydrate, magnesium stearate, modified pharmaceutical glaze, polyethylene glycol, polysorbate 80, povidone, propylene glycol, and titanium dioxide.
 
It sounds good to me. Reduces gyno more effectivly than tamoxofen citrate and lowers cholesterol. I would really like to find out more about it. Seems like it could be pricey though. 47.26 canadian for 28 60mg tabs.
 
Ive been looking at various studies, and it seems to lower IGF-1 signifigantly, but im trying to find out if it lowers it more so than nolvadex. Although when on AAS, IGF-1 lowering isnt much of a concern, in the study i read with raloxifene, it returned acromegalic women back to normal levels of igf-1.
 
Don't know a lot about it, guys. The only patients I've seen on it were for osteoporosis.
But it's newer than tamoxifen, and it's going to be pricey, until the next SERM comes along, then the price will go down. It's always the way.
 
Back
Top